Form 4: Astera Labs CFO Michael Tate Sells Shares Under 10b5-1 Trading Plan

Astera Labs' Chief Financial Officer, Michael Tate, sold a portion of his shares through a pre-arranged 10b5-1 trading plan.

Summary

• Michael Tate, the Chief Financial Officer of Astera Labs, Inc., executed multiple sales of common stock on December 4, 2024.
• These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on May 30, 2024.
• The transactions involved the sale of 17,000 shares of common stock at weighted average prices ranging from $115.4431 to $120.5836.
• The shares were sold in multiple transactions at varying prices within the ranges specified.
• Following these transactions, Mr. Tate directly owns 286,424 shares and indirectly owns 1,412,888 shares through the Tate Trust.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing a pre-planned stock sale by an executive. It does not contain any information that would significantly impact the sentiment of the stock.

Risks

• The sale of shares by a high-ranking executive could be perceived negatively by the market, potentially impacting investor confidence.
• The reliance on a 10b5-1 trading plan suggests a pre-determined strategy for selling shares, which may not reflect current market conditions or the executive's personal outlook on the company's future.

Industry Context

The filing is a routine disclosure of insider trading activity, which is common for publicly traded companies. It does not indicate any specific trend or event within the semiconductor industry.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies to avoid accusations of insider trading.
• The volume of shares sold is relatively small compared to the total outstanding shares of the company, which is typical for routine executive sales.
• Similar filings are regularly made by executives at comparable companies such as Marvell Technology, Broadcom, and NVIDIA.

Stakeholder Impact

• The sale of shares by the CFO could potentially cause a minor negative reaction from shareholders, although the pre-planned nature of the sales should mitigate this impact.

Key Dates

Keywords

Astera Labs, Michael Tate, SEC Form 4, 10b5-1 trading plan, insider trading, stock sale, CFO, ALAB